RCM
IOBT

RA Capital Management’s IO Biotech IOBT Stock Holding History

RA Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,127,260
Closed -$2.59M – 65
2022
Q4 		$2.59M Sell
1,127,260
-730,495
-39% -$1.93M 0.05% 63
2022
Q3 		$5.04M Hold
1,857,755
– – 0.11% 70
2022
Q2 		$8.68M Hold
1,857,755
– – 0.23% 62
2022
Q1 		$9.85M Hold
1,857,755
– – 0.21% 77
2021
Q4 		$11.9M Buy
+1,857,755
New +$17.9M 0.21% 75

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RA Capital Management's IOBT Position: Q1 2023 in Review

RA Capital Management sold out of IO Biotech (IOBT) in Q1 2023, closing a stake of 1,127,260 shares — an estimated $2.59M sold.

RA Capital Management first reported a position in IOBT in Q4 2021 and held it in 5 quarters. The position peaked at $11.9M in Q4 2021. 17 funds tracked by Wall St. Rank hold IOBT as of Q1 2023.

  • RA Capital Management reported no remaining IO Biotech position as of Q1 2023 after selling out during the quarter.
  • RA Capital Management sold 1,127,260 IO Biotech shares in Q1 2023, an estimated $2.59M.
  • RA Capital Management first reported a position in IO Biotech in Q4 2021 and held it in 5 quarters.
  • RA Capital Management's IO Biotech position peaked at $11.9M in Q4 2021.
  • 17 funds tracked by Wall St. Rank held IO Biotech as of Q1 2023.

Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.